NO20020792D0 - Behandling av rastlöse ben syndrom med en kombinasjon av clonidin og opioid - Google Patents

Behandling av rastlöse ben syndrom med en kombinasjon av clonidin og opioid

Info

Publication number
NO20020792D0
NO20020792D0 NO20020792A NO20020792A NO20020792D0 NO 20020792 D0 NO20020792 D0 NO 20020792D0 NO 20020792 A NO20020792 A NO 20020792A NO 20020792 A NO20020792 A NO 20020792A NO 20020792 D0 NO20020792 D0 NO 20020792D0
Authority
NO
Norway
Prior art keywords
clonidine
opioid
treatment
combination
restless leg
Prior art date
Application number
NO20020792A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020792L (no
Inventor
Hans-Michael Brecht
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20020792L publication Critical patent/NO20020792L/no
Publication of NO20020792D0 publication Critical patent/NO20020792D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20020792A 1999-08-19 2002-02-18 Behandling av rastlöse ben syndrom med en kombinasjon av clonidin og opioid NO20020792D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19938823A DE19938823A1 (de) 1999-08-19 1999-08-19 Medikamentöse Behandlung des Restless Leg Syndroms
PCT/EP2000/007719 WO2001013903A2 (de) 1999-08-19 2000-08-09 Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid

Publications (2)

Publication Number Publication Date
NO20020792L NO20020792L (no) 2002-02-18
NO20020792D0 true NO20020792D0 (no) 2002-02-18

Family

ID=7918572

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020792A NO20020792D0 (no) 1999-08-19 2002-02-18 Behandling av rastlöse ben syndrom med en kombinasjon av clonidin og opioid

Country Status (21)

Country Link
US (1) US20010053777A1 (es)
EP (1) EP1210076A2 (es)
JP (1) JP2003513014A (es)
KR (1) KR20020020273A (es)
CN (1) CN1368878A (es)
AR (1) AR025329A1 (es)
AU (1) AU6836500A (es)
BR (1) BR0013355A (es)
CA (1) CA2382648A1 (es)
CO (1) CO5190708A1 (es)
CZ (1) CZ2002516A3 (es)
DE (1) DE19938823A1 (es)
IL (1) IL147643A0 (es)
MX (1) MXPA02001295A (es)
NO (1) NO20020792D0 (es)
PE (1) PE20010738A1 (es)
PL (1) PL364871A1 (es)
SK (1) SK2452002A3 (es)
TR (1) TR200200450T2 (es)
UY (1) UY26296A1 (es)
WO (1) WO2001013903A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
HU1500214D0 (hu) 1997-12-22 2002-03-28 Euro Celtique Sa Opioid agonista és antagonista hatóanyagot tartalmazó gyógyszerkészítmény
EP1274430B1 (en) * 2000-04-21 2005-12-14 Pharmacia & Upjohn Company LLC Cabergoline for the treatment of fibromyalgia and chronic fatigue syndrome
CA2404704A1 (en) * 2000-04-21 2001-11-22 David W. Robertson Treatment of fibromyalgia and chronic fatigue syndrome
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
PT1380306E (pt) * 2001-03-30 2009-05-25 Toray Industries Medicamentos para psiconeurose
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
EP2425823A1 (en) 2002-04-05 2012-03-07 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
AU2003257418A1 (en) * 2002-06-19 2004-01-06 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
ATE295726T1 (de) 2002-12-02 2005-06-15 Sanol Arznei Schwarz Gmbh Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
JP5704789B2 (ja) * 2005-01-28 2015-04-22 ユーロ−セルティーク エス．エイ． 耐アルコール性剤形
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
WO2008079727A2 (en) * 2006-12-22 2008-07-03 Allergan, Inc. Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
US20110097393A1 (en) * 2008-06-25 2011-04-28 US WorldMeade, LLC Skin Patches and Sustained-Release Formulations Comprising Lofexidine for Transdermal and Oral Delivery
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
US20180264013A1 (en) * 2010-07-08 2018-09-20 Wellesley Pharmaceuticals, Llc Composition and methods for treating sleep disorders
CA2876203A1 (en) * 2012-06-11 2013-12-19 Psychogenics, Inc. Use of eltoprazine in the treatment of motor and movement disorders associated with the treatment of parkinson's disease
CN105517551A (zh) 2013-07-23 2016-04-20 欧洲凯尔特公司 用于在患有疼痛和导致肠生态失调和/或提高肠细菌移位风险之疾病的患者中治疗疼痛的羟考酮与纳洛酮的组合
KR101891185B1 (ko) 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
US20150098997A1 (en) 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
RU2018105761A (ru) 2013-10-07 2019-02-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
WO2018052926A1 (en) * 2016-09-13 2018-03-22 Mindlab LLC Medicine combinations and treatment of restless leg syndrome
PT3906927T (pt) * 2020-05-04 2022-07-27 Bioprojet Pharma Utilização de agonistas parciais da dopamina d3 para o tratamento de distúrbios do sistema nervoso central
CN115154448B (zh) * 2022-08-04 2024-01-30 谭竞 一种治疗不宁腿综合征的药物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859685A (en) * 1986-08-13 1989-08-22 Boc, Inc. Anesthetic composition and method of using the same
DE19758564A1 (de) * 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
AU3490300A (en) * 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
TR200200450T2 (tr) 2002-08-21
PE20010738A1 (es) 2001-07-16
CZ2002516A3 (cs) 2002-05-15
NO20020792L (no) 2002-02-18
AU6836500A (en) 2001-03-19
CA2382648A1 (en) 2001-03-01
WO2001013903A2 (de) 2001-03-01
IL147643A0 (en) 2002-08-14
DE19938823A1 (de) 2001-02-22
CO5190708A1 (es) 2002-08-29
PL364871A1 (en) 2004-12-27
JP2003513014A (ja) 2003-04-08
US20010053777A1 (en) 2001-12-20
AR025329A1 (es) 2002-11-20
BR0013355A (pt) 2002-04-30
WO2001013903A3 (de) 2001-08-23
CN1368878A (zh) 2002-09-11
SK2452002A3 (en) 2002-06-04
UY26296A1 (es) 2001-04-30
KR20020020273A (ko) 2002-03-14
MXPA02001295A (es) 2002-08-12
EP1210076A2 (de) 2002-06-05

Similar Documents

Publication Publication Date Title
NO20020792D0 (no) Behandling av rastlöse ben syndrom med en kombinasjon av clonidin og opioid
NO20021845L (no) Behandling av sovnforstyrrelser under anvendelse av desloratadin
NO20015773D0 (no) Forhindring og behandling av amyloidogen sykdom
NO20030725D0 (no) Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin
DK1309324T3 (da) Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X
NO20020793L (no) Virkestoffkombinasjon med clonidin
NO20052796D0 (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
EP1492433A4 (en) PIVOTABLE CONNECTION OF SUPPORT SPACER TO FOOT AND TABLE TRAY
NO20013380D0 (no) 2-aminobenzoksazinonderivater for behandling av fedme
NO20052420D0 (no) Farmakologisk behandling av sovnapn±.
NO20052009D0 (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
NO20052277D0 (no) Behandling av syndrom X med substituerte tetraliner og indaner
NO20015542D0 (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
NO20015772L (no) Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom
DK1164996T3 (da) Transdermalt terapeutisk system med nikotin og tilsat monoterpenketoner
NO20011537D0 (no) Kjemokinreseptorpeptidvaksiner for behandling og forebygging av diabetes
NO20020569D0 (no) Substituerte pyridaziner og kondenserte pyridaziner med angiogenese - inhiberende virkning
AU2003247841A8 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
NO20010464L (no) FremgangsmÕter og preparater for behandling av gastro- øsofagealt-reflukssyndrom
NO20014725D0 (no) Forbedret kreftbehandling med temozolomid
EE200100623A (et) Melatoniini terapeutiline kasutamine
NO20043693L (no) Profylaktisk og terapeutisk behandling av infektiose og andre sykdommer med immunoeffektorforbindelser
AU2003270815A8 (en) Treatment of irritable bowel syndrome and related bowel diseases
NO20000666D0 (no) Ammoniakkoksydasjon med redusert dannelse av N2O

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application